Print this article
- 12/14/2016

In brief: J&J ended discussions with Actelion Pharmaceuticals Ltd.

Pharma Horizon

Johnson & Johnson (NYSE: JNJ) today confirmed it has ended discussions with Actelion Pharmaceuticals Ltd. (SIX: ATLN) regarding a potential transaction. Johnson & Johnson was not able to reach an agreement that it believed would create adequate value for its shareholders.

 

Source: Johnson & Johnson press release